30.09.2020

Scope Fluidics intends to enter the Warsaw Stock Exchange regulated market in 2021

Scope Fluidics – a biotechnological company listed on NewConnect, developer of innovative medical diagnostics projects – has decided to change the company’s trading platform from NewConnect to the WSE regulated market. The dynamic growth of the company and flexible securing of project financing from the EIB are conducive to the listing of the company on the WSE regulated market.

– The development of our projects and growth of our entire company, along with favorable forecasts for the molecular diagnostics market, as well as the increasing market value of Scope Fluidics are the factors which let us seriously consider moving to the WSE regulated market. By doing so, we want to improve the recognition of Company’s brand and open up to a wider range of investors, including global investors. I also believe that the presence among the largest companies listed on the Polish stock exchange will strengthen our position on the med-tech market. This is also a step which follows the direction of Scope Fluidics’ long-term development plans – i.e. working on two or three projects in parallel says Szymon Ruta, Member of the Board, CFO of Scope Fluidics.

Scope Fluidics plans to change the trading platform in 2021. Currently, the Company starts analyses aimed at defining the optimal date, scenarios and conditions under which the company’s shares would be introduced to the WSE regulated market.

In order for Scope Fluidics to join the group of companies listed on the regulated market of the Warsaw Stock Exchange, it is necessary to take into account a number of criteria concerning, among others: benefits related to the expansion of the group of professional entities capable of investing in the Company’s shares (both Polish and foreign institutions); external economic conditions; the issue of increasing the Company’s credibility; financial and operational standing, possible events and circumstances which could be of strategic nature, as well as costs related to the Company’s debut on the WSE market.

The company is currently working on two innovative systems for medical diagnostics. Scope Fluidics is able to implement projects using various financial resources. Each project can be financed by means of grants as well as funds from the European Investment Bank and from Investors. Scope Fluidics takes steps to ensure that the sources of funding are as flexible and optimal as possible.